Key Highlights
- AffyImmune Therapeutics announces the appointment of Rick Rutter, Ph.D., and Jorge Nieva, M.D., to its Board of Directors.
- Appointments bolster AffyImmune’s AIC100 CAR T cell therapy development for advanced thyroid cancers and non-small cell lung cancer (NSCLC).
- Rutter and Nieva bring decades of experience in CMC regulatory strategy and clinical oncology.
- AffyImmune’s AIC100 is nearing completion of Phase 1 trials for thyroid cancer and moving toward Phase 2 for NSCLC.
Source: Business Wire
Notable Quotes
- “I am delighted to join AffyImmune’s Board and to work with the management team to bring industry-best CMC and supply chain practices, and ready AIC100 for registrational trials and commercial launch.” — Rick Rutter, Ph.D., Former Executive Vice President, Biotherapeutics Pharmaceutical Sciences at Pfizer; Expert Consultant
- “Joining AffyImmune’s Board of Directors is an exciting opportunity to contribute to the expansion of AIC100 beyond advanced thyroid cancers, into larger indications such as NSCLC.” — Jorge Nieva, M.D., Associate Professor of Clinical Medicine at Keck School of Medicine, University of Southern California
SoHC's Take
AffyImmune’s strategic appointments of Rick Rutter, Ph.D., and Jorge Nieva, M.D., signal a pivotal moment for the company as it progresses its innovative CAR T cell therapy, AIC100, toward advanced clinical trials. These new board members not only enhance the company’s expertise in regulatory strategy and oncology but also strengthen its ability to address significant unmet medical needs in thyroid cancer and NSCLC. This expansion marks a crucial step for AffyImmune as it readies AIC100 for commercialization, advancing toward transforming solid tumor treatment landscapes.
Heading
Key Highlights Heidi Chen named Chief Legal Officer at GeneDx, effective November 25, 2024. Brings over 30 years of legal ...
Key Highlights TA Associates completes a strategic growth investment in Vee Healthtek. Vee Healthtek to expand services in healthcare technology ...
Key Highlights Dr. Laura Aguilar named Chief Medical Officer at Diakonos Oncology. DOC1021 dendritic cell vaccine to enter Phase 2 ...
Key Highlights Deb Autor, former FDA Deputy Commissioner, joins Hims & Hers Board of Directors. Janet Stevens, pharmaceutical quality expert, named Global ...
Key Highlights Dr. Gregg A. Pratt joins as Chief Regulatory and Quality Assurance Officer to oversee regulatory and quality functions. Phase ...
Key Highlights Revisto secures $4M in seed funding led by LiveOak Ventures, joined by Eli Lilly and others. AI-driven platform ...
